Home/Pipeline/PSM101

PSM101

EGFR‑overexpressing solid tumors

PreclinicalActive

Key Facts

Indication
EGFR‑overexpressing solid tumors
Phase
Preclinical
Status
Active
Company

About PrecisemAb Biotech

A Taiwan biotech delivering safer, tumor‑selective antibodies via a protease‑activated lock technology.

View full company profile

Therapeutic Areas